We recently compiled a list of the 10 Worst ADR Stocks To Buy According to Short Sellers. In this article, we are going to ...

Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner ...

An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a foreign company.

"ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific" was originally created and published by Clinical ...

Bristol Myers Squibb is ending its collaboration with Immatics on IMA401, effective December 12, as part of portfolio ...

Certain types of tumors make up the majority of that 20%, such as melanoma, non-small cell lung cancer, and certain ...

Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the ...

Immatics presented more clinical data on its bispecific T cell engager at Europe's largest cancer conference. But the German and US biotech is losing its partner on the Phase 1 drug, which became one ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Immatics (IMTX – Research Report) on September 8. The company’s ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not ...